Yeh Shih Wei, Sami Naveed, Ahmed Razzaque A
Department of Oral Medicine, Harvard School of Dental Medicine, Boston, Massachusetts 02115, USA.
Am J Clin Dermatol. 2005;6(5):327-42. doi: 10.2165/00128071-200506050-00006.
Pemphigus vulgaris is a rare, chronic, autoimmune mucocutaneous blistering disease. The disease can progress to involve the skin and multiple mucosae. Pemphigus vulgaris can be associated with a high morbidity and significant mortality rate. Treatment of the condition can be challenging. Conventional therapy primarily consists of systemic corticosteroids and immunosuppressant agents. In some patients with pemphigus vulgaris, these agents fail to provide an effective clinical response or have significant adverse effects.
We evaluated data on 792 patients with pemphigus vulgaris retrieved from PubMed, covering the period 1973-2004. Only patients reported in the English literature were included in this review. Recently, several new therapeutic agents and treatment modalities have been described for the treatment of patients with pemphigus vulgaris. Some therapeutic agents that were used in the past and abandoned have recently regained favor. This review focuses on the therapeutic uses of dapsone, methotrexate, mycophenolate mofetil, chlorambucil, dexamethasone-cyclophosphamide pulse therapy, immunoablative therapy with cyclophosphamide, plasmapheresis, and extracorporeal photochemotherapy. Newer agents, such as intravenous immunoglobulin (IVIg) therapy and rituximab (an anti-CD20 chimeric monoclonal antibody), are also discussed.
Among the oral agents, dapsone may be considered a first-line agent. This is primarily because the risk of potentially fatal adverse effects with this drug is lower than that associated with other available chemotherapeutic agents. In patients who are refractory to oral agents, alternative treatments have been used to prevent further disease progression. Recently, the use of IVIg therapy, with a defined protocol, has been reported to be beneficial. This therapy is promising since it may allow for discontinuation of all other therapies and is safe. The adverse effects from IVIg therapy are minimal. Furthermore, compared with other therapies, it provides a better quality of life.
寻常型天疱疮是一种罕见的慢性自身免疫性黏膜皮肤水疱病。该病可进展累及皮肤和多个黏膜部位。寻常型天疱疮可伴有高发病率和显著死亡率。该病的治疗具有挑战性。传统治疗主要包括全身用皮质类固醇和免疫抑制剂。在一些寻常型天疱疮患者中,这些药物未能提供有效的临床反应或有显著不良反应。
我们评估了从PubMed检索到的1973年至2004年期间792例寻常型天疱疮患者的数据。本综述仅纳入英文文献报道的患者。最近,已描述了几种用于治疗寻常型天疱疮患者的新治疗药物和治疗方式。一些过去使用但已被弃用的治疗药物最近又重新受到青睐。本综述重点关注氨苯砜、甲氨蝶呤、霉酚酸酯、苯丁酸氮芥、地塞米松 - 环磷酰胺脉冲疗法、环磷酰胺免疫清除疗法、血浆置换和体外光化学疗法的治疗用途。还讨论了较新的药物,如静脉注射免疫球蛋白(IVIg)疗法和利妥昔单抗(一种抗CD20嵌合单克隆抗体)。
在口服药物中,氨苯砜可被视为一线药物。这主要是因为该药物潜在致命不良反应的风险低于其他可用化疗药物。对于口服药物难治的患者,已采用替代治疗以防止疾病进一步进展。最近,据报道按确定方案使用IVIg疗法是有益的。这种疗法很有前景,因为它可能允许停用所有其他疗法且安全。IVIg疗法的不良反应极小。此外,与其他疗法相比,它能提供更好的生活质量。